Main Menu

Publications Highlights View all by category

Types of Publications


Journal Articles

Bate, J., Baker, S., Breuer, J., Chisholm, J.C., Gray, J., Hambleton, S., Houlton, A., Jit, M., Lowis, S., Makin, G., et al. (2019). PEPtalk2: results of a pilot randomised controlled trial to compare VZIG and aciclovir as postexposure prophylaxis (PEP) against chickenpox in children with cancer. Archives of disease in childhood, Vol.104 (1), pp. 25-29.  show abstract

Vaarwerk, B., Schoot, R.A., Maurice-Stam, H., Slater, O., Hartley, B., Saeed, P., Gajdosova, E., van den Brekel, M.W., Balm, A.J., Hol, M.L., et al. (2019). Psychosocial well-being of long-term survivors of pediatric head-neck rhabdomyosarcoma. Pediatric blood & cancer, Vol.66 (2), pp. e27498-e27498.

Roy Moulik, N., Vaidya, S., Mandeville, H. & Chisholm, J.C. (2019). Managing peritoneal involvement in children and young people with rhabdomyosarcoma: A single‐center experience from the United Kingdom. Pediatric blood & cancer, Vol.66 (9).

Vaarwerk, B., Bisogno, G., McHugh, K., Brisse, H.J., Morosi, C., Corradini, N., Jenney, M., Orbach, D., Chisholm, J.C., Ferrari, A., et al. (2019). Indeterminate Pulmonary Nodules at Diagnosis in Rhabdomyosarcoma: Are They Clinically Significant? A Report From the European Paediatric Soft Tissue Sarcoma Study Group. Journal of clinical oncology, Vol.37 (9), pp. 723-730.

Gallego, S., Zanetti, I., Orbach, D., Ranchère, D., Shipley, J., Zin, A., Bergeron, C., de Salvo, G.L., Chisholm, J., Ferrari, A., et al. (2018). Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancer, Vol.124 (15), pp. 3201-3209.

Chisholm, J.C., Suvada, J., Dunkel, I.J., Casanova, M., Zhang, W., Ritchie, N., Choi, Y., Park, J., Das Thakur, M., Simko, S., et al. (2018). BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma. Pediatric blood & cancer, Vol.65 (5), pp. e26947-e26947.

Bisogno, G., Jenney, M., Bergeron, C., Gallego Melcón, S., Ferrari, A., Oberlin, O., Carli, M., Stevens, M., Kelsey, A., De Paoli, A., et al. (2018). Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. The lancet oncology, Vol.19 (8), pp. 1061-1071.

Moreno, L., Casanova, M., Chisholm, J.C., Berlanga, P., Chastagner, P.B., Baruchel, S., Amoroso, L., Gallego Melcón, S., Gerber, N.U., Bisogno, G., et al. (2018). Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer. European journal of cancer, Vol.100, pp. 27-34.

Ali, A., Mohamed, M., Chisholm, J. & Thway, K. (2017). Solid-Pattern Desmoplastic Small Round Cell Tumor. International journal of surgical pathology, Vol.25 (2), pp. 158-161.

Ferrari, A., Trama, A., De Paoli, A., Bergeron, C., Merks, J.H., Jenney, M., Orbach, D., Chisholm, J.C., Gallego, S., Glosli, H., et al. (2017). Access to clinical trials for adolescents with soft tissue sarcomas: Enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols. Pediatric blood & cancer, Vol.64 (6).

Selfe, J., Olmos, D., Al-Saadi, R., Thway, K., Chisholm, J., Kelsey, A. & Shipley, J. (2017). Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: Retrospective analyses of patients on UK trials. Pediatric blood & cancer, Vol.64 (7), pp. e26386-e26386.

Chisholm, J.C., Merks, J.H., Casanova, M., Bisogno, G., Orbach, D., Gentet, J.-., Thomassin-Defachelles, A.-., Chastagner, P., Lowis, S., Ronghe, M., et al. (2017). Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study). European journal of cancer, Vol.83, pp. 177-184.

Kieran, M.W., Chisholm, J., Casanova, M., Brandes, A.A., Aerts, I., Bouffet, E., Bailey, S., Leary, S., MacDonald, T.J., Mechinaud, F., et al. (2017). Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. Neuro-oncology, Vol.19 (11), pp. 1542-1552.

Clement, S.C., Schoot, R.A., Slater, O., Chisholm, J.C., Abela, C., Balm, A.J., van den Brekel, M.W., Breunis, W.B., Chang, Y.C., Davila Fajardo, R., et al. (2016). Endocrine disorders among long-term survivors of childhood head and neck rhabdomyosarcoma. European journal of cancer, Vol.54, pp. 1-10.

Phillips, R.S., Sung, L., Amman, R.A., Riley, R.D., Castagnola, E., Haeusler, G.M., Klaassen, R., Tissing, W.J., Lehrnbecher, T., Chisholm, J., et al. (2016). Predicting microbiologically defined infection in febrile neutropenic episodes in children: global individual participant data multivariable meta-analysis. British journal of cancer, Vol.114 (6), pp. 623-630.

Veal, G.J., Errington, J., Sastry, J., Chisholm, J., Brock, P., Morgenstern, D., Pritchard-Jones, K. & Chowdhury, T. (2016). Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens. Cancer chemotherapy and pharmacology, Vol.77 (4), pp. 685-692.

Herd, F., Bate, J., Chisholm, J., Johnson, E. & Phillips, B. (2016). Variation in practice remains in the UK management of paediatric febrile neutropenia: Table 1. Archives of disease in childhood, Vol.101 (4), pp. 410-411.

Carceller, F., Bautista, F.J., Fowkes, L.A., Marshall, L.V., Sirvent, S.I., Chisholm, J.C., Pearson, A.D., Koh, D.-. & Moreno, L. (2016). Response Assessment in Paediatric Phase I Trials According to RECIST Guidelines: Survival Outcomes, Patterns of Progression and Relevance of Changes in Tumour Measurements. Pediatric blood & cancer, Vol.63 (8), pp. 1400-1406.

Thway, K., Chisholm, J., Hayes, A., Swansbury, J. & Fisher, C. (2015). Pediatric low-grade fibromyxoid sarcoma mimicking ossifying fibromyxoid tumor: adding to the diagnostic spectrum of soft tissue tumors with a bony shell. Hum pathol, Vol.46 (3), pp. 461-466.  show abstract

Schoot, R.A., Slater, O., Ronckers, C.M., Zwinderman, A.H., Balm, A.J., Hartley, B., van den Brekel, M.W., Gupta, S., Saeed, P., Gajdosova, E., et al. (2015). Adverse events of local treatment in long-term head and neck rhabdomyosarcoma survivors after external beam radiotherapy or AMORE treatment. European journal of cancer, Vol.51 (11), pp. 1424-1434.

Norman, G., Fayter, D., Lewis-Light, K., Chisholm, J., McHugh, K., Levine, D., Jenney, M., Mandeville, H., Gatz, S. & Phillips, B., et al. (2015). An emerging evidence base for PET-CT in the management of childhood rhabdomyosarcoma: systematic review. Bmj open, Vol.5 (1), p. e006030.  show abstract

Gatz, S.A., Thway, K., Mandeville, H., Kerawala, C., MacVicar, D. & Chisholm, J. (2015). Chemotherapy responsiveness in a patient with multiply relapsed ameloblastic fibro-odontosarcoma of the maxilla. Pediatric blood & cancer, Vol.62 (11), pp. 2029-2032.

Lehrnbecher, T., Aplenc, R., Rivas Pereira, F., Lassaletta, A., Caselli, D., Kowalczyk, J., Chisholm, J., Sung, L. & Grp, S.I. (2014). Variations in non-pharmacological anti-infective measures in childhood leukemia - results of an international survey (vol 97, pg 1548, 2012). Haematologica, Vol.99 (7), pp. 1272-1272.

Morgenstern, D.A., Hargrave, D., Marshall, L.V., Gatz, S.A., Barone, G., Crowe, T., Pritchard-Jones, K., Zacharoulis, S., Lancaster, D.L., Vaidya, S.J., et al. (2014). Toxicity and outcome of children and adolescents participating in phase I/II trials of novel anticancer drugs: the Royal Marsden experience. J pediatr hematol oncol, Vol.36 (3), pp. 218-223.  show abstract

Calton, E.A., Le Doare, K., Appleby, G., Chisholm, J.C., Sharland, M., Ladhani, S.N. & Participants, C.A. (2014). Invasive Bacterial and Fungal Infections in Paediatric Patients with Cancer: Incidence, Risk Factors, Aetiology and Outcomes in aUK Regional Cohort 2009-2011. Pediatric blood & cancer, Vol.61 (7), pp. 1239-1245.

Norman, G., Fayter, D., Light-Lewis, K., Chisholm, J., Mandeville, H., Gatz, S., Levine, D., Jenney, M., McHugh, K. & Phillips, B., et al. (2014). THE ROLE OF PET-CT IN THE MANAGEMENT OF CHILDHOOD RHABDOMYOSARCOMA: SYSTEMATIC REVIEW. Pediatric blood & cancer, Vol.61, pp. S133-S133.

Schoot, R.A., Slater, O., Ronckers, C.M., Zwinderman, A.H., Balm, A.J., Hartley, B., van de Brekel, M., Gupta, S., Saeed, P., Gajdosova, E., et al. (2014). ADVERSE EVENTS OF LOCAL TREATMENT IN HEAD AND NECK RHABDOMYOSARCOMA SURVIVORS AFTER EXTERNAL BEAM RADIOTHERAPY OR AMORE TREATMENT. Pediatric blood & cancer, Vol.61, pp. S311-S311.

Bisogno, G., De Salvo, G.L., Bergeron, C., Carli, M., Ferrari, A., Jenney, M., Mercks, H., Kelsey, A., Gallego, S., Chisholm, J., et al. (2014). THE ROLE OF DOXORUBICIN IN THE TREATMENT OF RHABDOMYOSARCOMA: PRELIMINARY RESULTS FROM THE EPSSG RMS2005 RANDOMIZED TRIAL. Pediatric blood & cancer, Vol.61, pp. S133-S134.

Dommett, R., Chisholm, J., Turner, M., Bajaj-Elliott, M. & Klein, N.J. (2013). Mannose-binding lectin genotype influences frequency and duration of infectious complications in children with malignancy. J pediatr hematol oncol, Vol.35 (1), pp. 69-75.  show abstract

Bate, J., Gibson, F., Johnson, E., Selwood, K., Skinner, R. & Chisholm, J. (2013). Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients (NICE Clinical Guideline CG151). Archives of disease in childhood-education and practice edition, Vol.98 (2), pp. 73-75.

Bate, J., Gibson, F., Selwood, K., Skinner, R., Phillips, B. & Chisholm, J.C. (2013). A reaudit of current febrile neutropenia practice in UK paediatric oncology centres prior to implementation of NICE guidance. Archives of disease in childhood, Vol.98 (4), pp. 315-316.

Gibson, F., Chisholm, J., Blandford, E., Donachie, P., Hartley, J., Lane, S., Selwood, K., Skinner, R., Phillips, R. & CCLG Supportive Care Group, , et al. (2013). Developing a national 'low risk' febrile neutropenia framework for use in children and young people's cancer care. Support care cancer, Vol.21 (5), pp. 1241-1251.  show abstract

Orbach, D., Mosseri, V., Stevens, M., Rey, A., Gallelo, S., Kelsey, A., Christine, D., Brenann, B., Van Noesel, M., Gaze, M., et al. (2013). NON PARAMENINGEAL HEAD-AND-NECK RHABDOMYOSARCOMA IN CHILDREN AND ADOLESCENT: A VERY LONG TERM EXPERIENCE OF THE INTERNATIONAL SOCIETY OF PEDIATRIC ONCOLOGY MALIGNANT MESENCHYMAL TUMOR (SIOP-MMT) COMMITTEE. Pediatric blood & cancer, Vol.60, pp. 36-36.

Rousseau, R., Geoerger, B., Chisholm, J., Casanova, M., Merks, J., Monnet, A., Dhalluin, C. & Oberlin, O. (2013). THE BERNIE STUDY: A PHASE II STUDY EVALUATING ADDITION OF BEVACIZUMAB TO CHEMOTHERAPY IN CHILDREN AND ADOLESCENTS WITH METASTATIC RHABDOMYOSARCOMA AND NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA. Pediatric blood & cancer, Vol.60, pp. 92-92.

Schoot, R.A., McHugh, K., van Rijn, R.R., Kremer, L.C., Chisholm, J.C., Caron, H.N. & Merks, J.H. (2013). Response assessment in pediatric rhabdomyosarcoma: can response evaluation criteria in solid tumors replace three-dimensional volume assessments?. Radiology, Vol.269 (3), pp. 870-878.  show abstract

Williamson, D., Missiaglia, E., Chisholm, J. & Shipley, J. (2012). Inconvenience of convenience cohorts--letter. Cancer epidemiol biomarkers prev, Vol.21 (8), p. 1388.

Bate, J., Chisholm, J., Skinner, R., Breuer, J., Ramsay, M., Wheatley, K., Hambleton, S. & Heath, P.T. (2012). Varicella post-exposure prophylaxis in children with cancer: urgent need for a randomised controlled trial. Archives of disease in childhood, Vol.97 (9), pp. 853-854.

Chisholm, J., Phillips, P., Sutton, A., Riley, R., Picton, S. & Stewart, L. (2012). Predicting Infectious Complications in Neutropenic Children and young people with Cancer Optimizing risk predictive strategies in febrile neutropenic episodes in children and young people undergoing treatment for malignant disease. Systematic reviews in pharmacy, .

Missiaglia, E., Williamson, D., Chisholm, J., Wirapati, P., Pierron, G., Petel, F., Concordet, J.-., Thway, K., Oberlin, O., Pritchard-Jones, K., et al. (2012). PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J clin oncol, Vol.30 (14), pp. 1670-1677.  show abstract

George, S.L., Broster, S., Chisholm, J.C. & Brock, P. (2012). Docetaxel in the treatment of children with refractory or relapsed hepatoblastoma. J pediatr hematol oncol, Vol.34 (7), pp. e295-e297.  show abstract

Lehrnbecher, T., Aplenc, R., Rivas Pereira, F., Lassaletta, A., Caselli, D., Kowalczyk, J., Chisholm, J., Sung, L. & Grp, S.I. (2012). Variations in non-pharmacological anti-infective measures in childhood leukemia - results of an international survey. Haematologica-the hematology journal, Vol.97 (10), pp. 1548-1552.

Missiaglia, E., Williamson, D., Chisholm, J., Wirapati, P., Pierron, G., Petel, F., Concordet, J.-., Thway, K., Oberlin, O., Pritchard-Jones, K., et al. (2012). Questionable Universal Validity of PAX3/FOXO1 Fusion Gene Status As Molecular Marker for Improvement of Risk Stratification in Rhabdomyosarcoma Therapy Reply. Journal of clinical oncology, Vol.30 (32), pp. 4040-4041.

Geoerger, B., Aerts, I., Casanova, M., Chisholm, J., Hargrave, D., Leary, S.E., Ashley, D., Bouffet, E., MacDonald, T., Di Giannatale, A., et al. (2012). UPDATED RESULTS FROM A PHASE I STUDY OF LDE225, A SMOOTHENED ANTAGONIST, IN PEDIATRIC PATIENTS WITH RECURRENT MEDULLOBLASTOMA OR OTHER SOLID TUMORS. Pediatric blood & cancer, Vol.59 (6), pp. 980-980.

Patel, S.R., Bate, J., Mathews, R., Chisholm, J. & Heath, P.T. (2012). VACCINATION STATUS OF CHILDREN WITH CANCER AFTER COMPLETION OF STANDARD-DOSE CHEMOTHERAPY AND AFTER HAEMATOPOIETIC STEM CELL TRANSPLANT. Pediatric blood & cancer, Vol.59 (6), pp. 1116-1116.

Morgenstern, D., Hargrave, D., Marshall, L.V., Gatz, S.A., Barone, G., Crowe, T., Pritchard-Jones, K., Zacharoulis, S., Lancaster, D.L., Vaidya, S.J., et al. (2012). EARLY PHASE CLINICAL TRIALS IN PAEDIATRIC ONCOLOGY THE ROYAL MARSDEN EXPERIENCE. Pediatric blood & cancer, Vol.59 (6), pp. 1091-1091.

Geoerger, B., Chisholm, J., Le Deley, M.-., Gentet, J.-., Zwaan, C.M., Dias, N., Jaspan, T., Mc Hugh, K., Couanet, D., Hain, S., et al. (2011). Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study. Eur j cancer, Vol.47 (2), pp. 230-238.  show abstract

Chisholm, J.C., Marandet, J., Rey, A., Scopinaro, M., de Toledo, J.S., Merks, J.H., O'Meara, A., Stevens, M.C. & Oberlin, O. (2011). Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy. J clin oncol, Vol.29 (10), pp. 1319-1325.  show abstract

Slade, I., Bacchelli, C., Davies, H., Murray, A., Abbaszadeh, F., Hanks, S., Barfoot, R., Burke, A., Chisholm, J., Hewitt, M., et al. (2011). DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. J med genet, Vol.48 (4), pp. 273-278.  show abstract

Bate, J., Chisholm, J., Heath, P.T., Breuer, J., Skinner, R., Manley, S., Patel, S., Wheatley, K., Ramsay, M., Kearns, P.R., et al. (2011). PEPtalk: postexposure prophylaxis against varicella in children with cancer. Archives of disease in childhood, Vol.96 (9), pp. 841-845.

Lehrnbecher, T., Aplenc, R., Pereira, F.R., Lassaletta, A., Caselli, D., Kowalczyk, J., Chisholm, J. & Sung, L. (2011). INSTITUTIONAL VARIATIONS IN NON-PHARMACOLOGICAL ANTI-INFECTIVE MEASURES - RESULTS OF AN INTERNATIONAL SURVEY. Pediatric blood & cancer, Vol.57 (5), pp. 847-847.

Bate, J., Patel, S.R., Chisholm, J., Heath, P.T. & CCLG, (2010). Immunisation Practices of Paediatric Oncology and Shared Care Oncology Consultants: A United Kingdom Survey. Pediatric blood & cancer, Vol.54 (7), pp. 941-946.

Jorgensen, M., Bate, J., Gatscher, S. & Chisholm, J.C. (2010). Invasive pneumococcal disease following treatment for choroid plexus carcinoma. Support care cancer, Vol.18 (5), pp. 647-650.  show abstract

Rees, H., Andrews, M., Broster, S., Nicholson, J., Skinner, R., Chisholm, J. & Canc, S.C. (2010). Influenza vaccination during cancer therapy. Archives of disease in childhood, Vol.95 (7).

Chisholm, J., Marandet, J., Rey, A. & Oberlin, O. (2010). PROGNOSTIC FACTORS AFTER RELAPSE IN NON-METASTATIC RHABDOMYOSARCOMA: WHO CAN BE SALVAGED?. Pediatric blood & cancer, Vol.55 (5), pp. 836-836.

Schoot, R., McHugh, K., van Rijn, R., Chisholm, J. & Merks, J. (2010). ARE THE RECIST CRITERIA USEFUL IN ASSESSING RESPONSE IN PAEDIATRIC RHABDOMYOSARCOMA?. Pediatric blood & cancer, Vol.55 (5), pp. 901-902.

Chisholm, J.C., Casanova, M., Geoerger, B., Merks, J.H., Massimini, G., Moore, N., Rooney, I.A., Viviers, L. & Oberlin, O. (2010). A phase II study evaluating addition of bevacizumab to chemotherapy in childhood and adolescent patients presenting with metastatic rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS). Journal of clinical oncology, Vol.28 (15).

Gibson, F., Hartley, J., Lane, S., Phillips, R., Selwood, K., Skinner, R. & Chisholm, J. (2009). Reaching A National Consensus On An Approach To Low Risk Febrile Neutropenia: The Challenges of A Delphi Survey. European journal of oncology nursing, Vol.13 (1), pp. 63-63.

Thomas, L., Baggen, L., Chisholm, J. & Sharland, M. (2009). Diagnosis and treatment of aspergillosis in children. Expert review of anti-infective therapy, Vol.7 (4), pp. 461-472.

Bate, J., Ladhani, S., Sharland, M., Chisholm, J., Lamagni, T., Ramsay, M., Johnson, A. & Pebody, R. (2009). Infection-Related Mortality in Children With Malignancy in England and Wales, 2003-2005. Pediatric blood & cancer, Vol.53 (3), pp. 371-374.

Dommett, R., Geary, J., Freeman, S., Hartley, J., Sharland, M., Davidson, A., Tulloh, R., Taj, M., Stoneham, S. & Chisholm, J.C., et al. (2009). Successful introduction and audit of a step-down oral antibiotic strategy for low risk paediatric febrile neutropaenia in a UK, multicentre, shared care setting. European journal of cancer, Vol.45 (16), pp. 2843-2849.

Patel, S.R., Chisholm, J.C. & Heath, P.T. (2008). Vaccinations in children treated with standard-dose cancer therapy or hematopoietic stem cell transplantation. Pediatric clinics of north america, Vol.55 (1), pp. 169-+.

Laddie, J. & Chisholm, J. (2007). A survey of parent and staff views on management by risk stratification in children with febrile neutropenia (FN). Pediatric blood & cancer, Vol.49 (4), pp. 508-509.

Phillips, R., Skinner, R. & Chisholm, J.C. (2007). Treating low-risk febrile neutropenia: Jenny's story. Archives of disease in childhood, Vol.92 (1), pp. 7-8.

Andrews, M., Chisholm, J., Nicholson, J., Broster, S. & Rees, H. (2007). Cross-sectional survey of influenza vaccination uptake in children with cancer. Pediatric blood & cancer, Vol.49 (4), pp. 509-509.

Chisholm, J.C. (2007). Reimmunization after therapy for childhood cancer. Clinical infectious diseases, Vol.44 (5), pp. 643-645.

Phillips, B., Selwood, K., Lane, S.M., Skinner, R., Gibson, F. & Chisholm, J.C. (2007). Variation in policies for the management of febrile neutropenia in United Kingdom Children's Cancer Study Group centres. Archives of disease in childhood, Vol.92 (6), pp. 495-498.

Chisholm, J.C., Machin, D., McDowell, H., McHugh, K., Ellershaw, C., Jenney, M., Foot, A.B. & Children's Cancer and Leukaemia Group (CCLG; formerly United Kingdom Children's Cancer Study Group), (2007). Efficacy of carboplatin given in a phase II window study to children and adolescents with newly diagnosed metastatic soft tissue sarcoma. Eur j cancer, Vol.43 (17), pp. 2537-2544.  show abstract

Duncan, C., Chisholm, J.C., Freeman, S., Riley, U., Sharland, M. & Pritchard-Jones, K. (2007). A prospective study of admissions for febrile neutropenia in secondary paediatric units in South East England. Pediatr blood cancer, Vol.49 (5), pp. 678-681.  show abstract

Fowler, D.J., Chisholm, J., Roebuck, D., Newman, L., Malone, M. & Sebire, N.J. (2006). Melanotic neuroectodermal tumor of infancy: clinical, radiological, and pathological features. Fetal pediatr pathol, Vol.25 (2), pp. 59-72.  show abstract

Fowler, D.J., Malone, M., Chisholm, J., Roebuck, D. & Sebire, N.J. (2006). Primary thoracic myxoid variant of extrarenal rhabdoid tumor in childhood. Fetal pediatr pathol, Vol.25 (3), pp. 159-168.  show abstract

Chisholm, J.C. & Dommett, R. (2006). The evolution towards ambulatory and day-case management of febrile neutropenia. Br j haematol, Vol.135 (1), pp. 3-16.  show abstract

Chisholm, J., Rubie, H., Desfachalles, S., Morland, B., Munzer, C., Valteau-Couanet, D., Mosseri, V., Bergeron, C., Weston, C., Coze, C., et al. (2006). A Phase II study of Temozolomide in relapsed or refractory high-risk Neuroblastoma. Journal of clinical oncology, (24(33)), pp. 5259-5264.

Chisholm, J., Howe, K., Taj, M. & Zambon, M. (2005). Influenza immunisation in children with solid tumours. European journal of cancer, Vol.41 (15), pp. 2280-2287.

Veal, G.J., Cole, M., Errington, J., Parry, A., Hale, J., Pearson, A.D., Howe, K., Chisholm, J.C., Beane, C., Brennan, B., et al. (2005). Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study. Clin cancer res, Vol.11 (16), pp. 5893-5899.  show abstract

Tischkowitz, M.D., Chisholm, J., Gaze, M., Michalski, A. & Rosser, E.M. (2004). Medulloblastoma as a first presentation of fanconi anemia. J pediatr hematol oncol, Vol.26 (1), pp. 52-55.  show abstract

Little, M.A., Morland, B., Chisholm, J., Hole, A., Shankar, A., Devine, T., Easlea, D., Meyer, L.C. & Pinkerton, C.R. (2002). A randomised study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHL. Med pediatr oncol, Vol.38 (2), pp. 98-103.  show abstract

Chisholm, J.C., Devine, T., Charlett, A., Pinkerton, C.R. & Zambon, M. (2001). Response to influenza immunisation during treatment for cancer. Arch dis child, Vol.84 (6), pp. 496-500.  show abstract

Chisholm, J., Devine, T., Dick, G., Mycroft, J. & Pinkerton, C.R. (2000). Safety and tolerability of Amphotericin B Lipid Complex (Abelcet). International journal of pediatric hematology/oncology, Vol.6 (6), pp. 393-402.

Chisholm, J., Devine, T., Mycroft, J. & Pinkerton, C.R. (1999). Liposomal amphotericin B (AmBisome) in children with febrile neutropenia and renal dysfunction. International journal of pediatric hematology/oncology, Vol.6 (3), pp. 173-182.

Chisholm, J.C., Devine, T., Mycroft, J. & Pinkerton, C.R. (1998). Tolerability of amphotericin B lipid complex (ABELCET) in children with malignant disease. Bone marrow transplantation, Vol.21, pp. S145-S145.

Veys, P.A., Meral, A., Hassan, A., Goulden, N., Chisholm, J., New, H., Armstrong, J., Bennett-Rees, N., Webb, D. & Gerritsen, B., et al. (1998). Improved outcome for blood and marrow transplantation in immunodeficiency. Bone marrow transplantation, Vol.21, pp. S128-S128.


Conferences

Vaarwerk, B., van der Lee, J.H., Breunis, W.B., Orbach, D., Chisholm, J.C., Cozic, N., Jenney, M., van Rijn, R.R., McHugh, K., Gallego, S., et al. (2018). Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study, Cancer, Vol.124 (5), pp.1016-1024.

Vaarwerk, B., Zanetti, I., De Salvo, G.L., Corradini, N., Jenney, M., Orbach, D., Chisholm, J., Ferraris, A., Morosi, C., Brisse, H., et al. (2018). Indeterminate Pulmonary Nodules at Diagnosis in Pediatric Rhabdomyosarcoma: AreWe Undertreating Patients? A Report from the European Paediatric Soft Tissue Sarcoma Study Group-RMS-2005 Study, PEDIATRIC BLOOD & CANCER, Vol.65, pp.S2-S3.

Bisogno, G., De Salvo, G.L., Bergeron, C., Jenney, M., Merks, J.H., Minard-Colin, V., Orbach, D., Glosli, H., Chisholm, J., Casanova, M., et al. (2018). Maintenance low-dose chemotherapy in patients with high-risk (HR) rhabdomyosarcoma (RMS): A report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)., JOURNAL OF CLINICAL ONCOLOGY, Vol.36 (18).

Federman, N., Albert, C.M., Turpin, B., Mascarenhas, L., Nagasubramanian, R., Geoerger, B., Casanova, M., Gallego Melcon, M.S., Chisholm, J., Van Tilburg, C.M., et al. (2017). Phase 1/2 study of the selective TRK inhibitor larotrectinib in pediatric patients with cancer., Journal of Clinical Oncology, Vol.35 (15_suppl), p.TPS10577.

Amakye, D., Robinson, D., Rose, K., Cho, Y.-., Ligon, K.L., Sharp, T., Ando, Y., Geoerger, B., Doz, F., Ashley, D., et al. (2013). DEVELOPMENT OF A FIVE-GENE HEDGEHOG SIGNATURE AS A PATIENT PRESELECTION TOOL FOR HEDGEHOG PATHWAY-TARGETED THERAPY IN MEDULLOBLASTOMA, NEURO-ONCOLOGY, Vol.15, pp.33-34.

Chisholm, J. (2013). Biology-driven strategy for new drug development in rhabdomyosarcoma, EUROPEAN JOURNAL OF CANCER, Vol.49, p.S47.

Kieran, M., Geoerger, B., Casanova, M., Chisholm, J., Aerts, I., Bouffet, E., Brandes, A.A., Leary, S.E., Sullivan, M., Bailey, S., et al. (2013). A PHASE 1/2 SAFETY AND PRELIMINARY EFFICACY STUDY OF SONIDEGIB (LDE225), A HEDGEHOG PATHWAY INHIBITOR, IN PEDIATRIC AND ADULT PATIENTS WITH RELAPSED OR REFRACTORY MEDULLOBLASTOMA AND OTHER SOLID TUMORS, NEURO-ONCOLOGY, Vol.15, p.115.

Missiaglia, E., Williamson, D., Chisholm, J.C., Wirapati, P., Pierron, G., Thway, K., Oberlin, O., Pritchard-Jones, K., Delattre, O., Delorenzi, M., et al. (2012). Development of prognostic molecular markers in pediatric rhabdomyosarcoma based on gene expression and copy number variations., JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (15).

Geoerger, B., Aerts, I., Casanova, M., Chisholm, J.C., Hargrave, D.R., Leary, S., Ashley, D.M., Bouffet, E., MacDonald, T., Hurh, E., et al. (2012). A phase I/II study of LDE225, a smoothened (Smo) antagonist, in pediatric patients with recurrent medulloblastoma (MB) or other solid tumors., JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (15).

Chisholm, J.C., Casanova, M., Merks, J.H., Geoerger, B., Rousseau, R.F., Moore, N., Dhalluin, C., Oberlin, O., Therapies, E.I. & Tissue, E.P., et al. (2012). The BERNIE study: A phase II study evaluating addition of bevacizumab (Bv) to chemotherapy in children and adolescents with metastatic rhabdomyosarcoma ( mRMS) and non-rhabdomyosarcoma soft tissue sarcoma (mNRSTS), JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (15).

Chisholm, J.C. (2011). Soft-tissue Sarcomas, EUROPEAN JOURNAL OF CANCER, Vol.47, pp.S25-S26.

Fowler, D.J., Chisholm, J., Roebuck, D., Malone, M., Anderson, G. & Sebire, N.J. (2006). Primary thoracic Myxoid variant of extrarenal rhabdoid tumor in childhood, JOURNAL OF PATHOLOGY, Vol.208, p.22A.

Dommett, R.M., Bajaj-Elliott, M., Chisholm, J. & Klein, N. (2006). Influence of mannose binding lectin (MBL) gene polymorphisms on infectious complications during treatment for childhood malignancy., BLOOD, Vol.108 (11), p.370A.

Rubie, H., Chisholm, J., Defachelles, A.S., Morland, B., Munzer, C., Valteau-Couanet, D., Mosseri, V., Bergeron, C., Weston, C., Coze, C., et al. (2006). Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: A Joint Societe' Francaise des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study, JOURNAL OF CLINICAL ONCOLOGY, Vol.24 (33), pp.5259-5264.

In this section

Research overview Publications